Literature DB >> 12091376

Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings.

Alvaro Urbano-Ispizua1, Ciril Rozman, Pedro Pimentel, Carlos Solano, Javier de la Rubia, Salut Brunet, Jaime Pérez-Oteyza, Christelle Ferrá, Javier Zuazu, Dolores Caballero, Joan Bargay, Alzira Carvalhais, Jose Luis Díez, Ildefonso Espigado, Adrián Alegre, Montserrat Rovira, Fernando Campilho, Jesús Odriozola, Miguel Angel Sanz, Jordi Sierra, Javier García-Conde, Emili Montserrat.   

Abstract

A study on 315 patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings was performed to determine risk factors for acute GVHD (aGVHD). Recipients of a dose of CD34+ cells (x 10(6)/kg) of 2 or less, more than 2 to 4, and more than 4 had a cumulative incidence of aGVHD grades I-IV of 21%, 35%, and 43%, respectively (log-rank P =.01); similarly, recipients of a dose of CD3+ cells (x 10(6)/kg) of 0.05 or less, more than 0.05 to 0.1, and more than 0.1 had a cumulative incidence of aGVHD grades I-IV of 18%, 35%, and 44%, respectively (log-rank P =.007). Using a Cox regression model, 4 independent factors for aGVHD I-IV were identified: increased CD34+ cell dose (P =.02), increased CD3+ cell dose (P =.02), female patients (P =.01), and higher patient age (> 42 years) (P =.007). This study shows, for the first time in T-cell-depleted transplantations, a positive correlation between the number of CD34+ cells and aGVHD and, also, that the number of CD3+ cells necessary to initiate aGVHD is lower than previously reported.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091376     DOI: 10.1182/blood-2001-11-0057

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Aristeidis Chaidos; Scott Patterson; Richard Szydlo; Mohammed Suhail Chaudhry; Francesco Dazzi; Edward Kanfer; Donald McDonald; David Marin; Dragana Milojkovic; Jiri Pavlu; John Davis; Amin Rahemtulla; Katy Rezvani; John Goldman; Irene Roberts; Jane Apperley; Anastasios Karadimitris
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

2.  High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT.

Authors:  Katayoun Rezvani; Stephan Mielke; Mojgan Ahmadzadeh; Yasemin Kilical; Bipin N Savani; Josette Zeilah; Keyvan Keyvanfar; Aldemar Montero; Nancy Hensel; Roger Kurlander; A John Barrett
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

3.  Allogeneic T cells induce rapid CD34+ cell differentiation into CD11c+CD86+ cells with direct and indirect antigen-presenting function.

Authors:  Javaneh Abbasian; Dolores Mahmud; Nadim Mahmud; Sandeep Chunduri; Hiroto Araki; Pavan Reddy; Ronald Hoffman; Mario Arpinati; James L M Ferrara; Damiano Rondelli
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

4.  High frequencies of CD62L⁺ naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation.

Authors:  S-Y Lu; K-Y Liu; D-H Liu; L-P Xu; X-J Huang
Journal:  Clin Exp Immunol       Date:  2011-06-02       Impact factor: 4.330

5.  Long-term results after transplantation of CD34+ selected (CellPro) versus unselected peripheral blood progenitor cells (PBPC) from related allogeneic donors.

Authors:  Hans-Georg Kopp; Stefan Wirths; Christoph Faul; Wolfgang Bethge; Stefan Scheding; Wolfram Brugger; Lothar Kanz; Wichard Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-09       Impact factor: 4.553

6.  Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

Authors:  Ekaterina Doubrovina; Banu Oflaz-Sozmen; Susan E Prockop; Nancy A Kernan; Sara Abramson; Julie Teruya-Feldstein; Cyrus Hedvat; Joanne F Chou; Glenn Heller; Juliet N Barker; Farid Boulad; Hugo Castro-Malaspina; Diane George; Ann Jakubowski; Guenther Koehne; Esperanza B Papadopoulos; Andromachi Scaradavou; Trudy N Small; Ramzi Khalaf; James W Young; Richard J O'Reilly
Journal:  Blood       Date:  2011-12-02       Impact factor: 22.113

7.  Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.

Authors:  Pere Barba; Patrick Hilden; Sean M Devlin; Molly Maloy; Djamilia Dierov; Jimmy Nieves; Matthew D Garrett; Julie Sogani; Christina Cho; Juliet N Barker; Nancy A Kernan; Hugo Castro-Malaspina; Ann A Jakubowski; Guenther Koehne; Esperanza B Papadopoulos; Susan Prockop; Craig Sauter; Roni Tamari; Marcel R M van den Brink; Scott T Avecilla; Richard Meagher; Richard J O'Reilly; Jenna D Goldberg; James W Young; Sergio Giralt; Miguel-Angel Perales; Doris M Ponce
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-23       Impact factor: 5.742

Review 8.  Prevention of GVHD without losing GVL effect: windows of opportunity.

Authors:  Ping Zhang; Benny J Chen; Nelson J Chao
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

9.  T Regulatory Cells in Donor Grafts May Predict the Severity of Acute Graft Versus Host Disease After Matched Sibling Donor Allogenic Peripheral Blood Stem Cell Transplantation.

Authors:  Dinesh Chandra; Jasdeep Singh; Roopam Deka; Ankur Ahuja; Rahul Sharma; Pravas Mishra; Tulika Seth; Manoranjan Mahapatra; Lalit Kumar; Seema Tyagi; Renu Saxena; Hara Prasad Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2019-01-07       Impact factor: 0.900

Review 10.  Advances in predicting acute GVHD.

Authors:  Andrew C Harris; James L M Ferrara; John E Levine
Journal:  Br J Haematol       Date:  2012-12-04       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.